Business
Rockwell Medical, Inc. Appoints Russell H. Ellison, MD, MSc, to Board of Directors
WIXOM, Mich., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company
About this update from Rockwell Medical, Inc.
[{"type":"text","content":"WIXOM, Mich., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the \"Company\"), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced today the appointment of Russell H. Ellison, MD, MSc, to its Board of Directors, effective January 9, 2020.\n Dr. Ellison has held leadership positions in both emerging biotechnology and large pharmaceutical companies for more than four decades. His broad experience includes board of director, chief executive and medical executive roles, with expertise in medical strategy, clinical development, global medical affairs, regulatory affairs and public health policy in major markets and developing countries. Dr. Ellison has a deep understanding of the renal space based on experiences with companies developing therapeutic products that address kidney disease and renal anemia, including Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors. “Russell’s broad industry experience with public biotechnology companies and especially his extensive knowledge of the renal and anemia space makes him an ideal addition to our Board. His leadership will serve us well as we commercialize and develop Triferic® (ferric pyrophosphate citrate) for hemodialysis patients around the world, implement our plans for building a leading medical organization, and further the clinical development of our therapeutic platform as we seek to transform the way anemia is managed in a variety of disease states,” stated John P. McLaughlin, Chairman of the Board of Directors of Rockwell Medical. “It is an honor to join Rockwell Medical’s Board and to have the opportunity to contribute to the advancement of such an innovative therapeutic. There is a global opportunity for Triferic® (ferric pyrophosphate citrate), and I am eager to work alongside the current Board members and management team to guide the path forward and ensure that patients have access to this unique iron maintenance therapy,” said Russell H. Ellison, MD, MSc. Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, Inc., which focused on, among other indications, kidney fibrosis, and successfully completed the company’s strategic sale in December 2018...